View Future GrowthTecan Group 過去の業績過去 基準チェック /06Tecan Groupの収益は年間平均-25.5%の割合で減少していますが、 Life Sciences業界の収益は年間 減少しています。収益は年間3.8% 0.9%割合で 増加しています。主要情報-25.46%収益成長率-26.64%EPS成長率Life Sciences 業界の成長21.51%収益成長率0.88%株主資本利益率-9.61%ネット・マージン-12.54%次回の業績アップデート11 Aug 2026最近の業績更新お知らせ • Dec 19Tecan Group AG to Report First Half, 2026 Results on Aug 11, 2026Tecan Group AG announced that they will report first half, 2026 results on Aug 11, 2026お知らせ • Oct 10Tecan Group AG to Report Fiscal Year 2025 Results on Mar 16, 2026Tecan Group AG announced that they will report fiscal year 2025 results on Mar 16, 2026お知らせ • Mar 06Tecan Group AG to Report Q4, 2024 Results on Jun 12, 2025Tecan Group AG announced that they will report Q4, 2024 results at 6:00 AM, Central European Standard Time on Jun 12, 2025お知らせ • Dec 17Tecan Group AG to Report First Half, 2025 Results on Aug 12, 2025Tecan Group AG announced that they will report first half, 2025 results on Aug 12, 2025お知らせ • Feb 06Tecan Group AG to Report First Half, 2024 Results on Aug 13, 2024Tecan Group AG announced that they will report first half, 2024 results on Aug 13, 2024お知らせ • Aug 16Tecan Group AG to Report Fiscal Year 2023 Results on Mar 12, 2024Tecan Group AG announced that they will report fiscal year 2023 results on Mar 12, 2024すべての更新を表示Recent updatesお知らせ • Apr 16Tecan Group Ag Announces Executive ChangesTecan Group AG in its AGM meeting held on April 15, 2026, announced that shareholders elected three new members of the Board of Directors: Nina Beikert, Gitte Pugholm Aabo and Guillaume Daniellot. Matthias Gillner, who has been a member of the Board of Directors since 2023 and its Vice-Chairman, was elected as the new Chairman. He will step down as Chair of the Audit Committee but will remain a member, alongside Guillaume Daniellot and Gitte Pugholm Aabo. With the addition of the newly elected members, the Board of Directors will once again comprise seven members, ensuring an optimal balance of expertise, skills, and experience for the future. Lukas Braunschweiler, Chairman and a member of the Board since 2018, did not stand for re-election.お知らせ • Mar 30The Tecan Group Announces the Appointment of Camila Japur as Chief Financial Officer, Effective on June 1, 2026The Tecan Group announced the appointment of Camila Japur as Chief Financial Officer, who will join the company on June 1, 2026. Camila currently serves as Group CFO of u-blox, where she has successfully led transformation initiatives, driving cost efficiency, strengthening financial processes, and enhancing capital market engagement. Prior to this, Camila spent 24 years at Ericsson, including seven years as CFO for the Enterprise Segment. Camila has an MBA from Fundação Getulio Vargas in São Paulo and a Bachelor's Degree in Economics from Universidade Mackenzie in São Paulo.お知らせ • Mar 25Tecan Group AG Announces Member of the Board of Directors Oliver Fetzer Will Not Stand for Re-ElectionTecan Group AG announced that Oliver Fetzer, a member of the Board since 2011, has decided not to stand for re-election at the AGM to be held on April 15, 2026.お知らせ • Mar 16+ 1 more updateTecan Group AG Proposes Dividend for the Full Year 2025The Board of Directors of Tecan Group AG will propose an unchanged dividend of CHF 3.00 per share at the Annual General Meeting on April 15, 2026 for the full year 2025. Half of the dividend, i.e., CHF 1.50, will again be paid out from the available capital contribution reserve and is therefore not subject to withholding tax.お知らせ • Dec 19Tecan Group AG to Report First Half, 2026 Results on Aug 11, 2026Tecan Group AG announced that they will report first half, 2026 results on Aug 11, 2026お知らせ • Dec 05Tecan Group AG, Annual General Meeting, Apr 15, 2026Tecan Group AG, Annual General Meeting, Apr 15, 2026.お知らせ • Dec 04ecan Group AG Announces Chairman of the Board of Directors Lukas Braunschweiler Will Not Stand for Re-ElectionTecan Group AG announced that Lukas Braunschweiler, Chairman of the Board of Directors and a member of the Board since 2018, will not stand for re-election.お知らせ • Dec 02Tecan Group AG (SWX:TECN) acquired Wako Automation.Tecan Group AG (SWX:TECN) acquired Wako Automation on December 1, 2025. Tecan Group AG (SWX:TECN) completed the acquisition of Wako Automation on December 1, 2025.お知らせ • Nov 17+ 1 more updateTecan Group AG Announces Departure of Tania Micki as Member of the Management BoardTecan Group AG announced that Tania Micki, member of the Management Board since February 2020, will be leaving the company to pursue an external opportunity. She will continue in her role through May 2026 to ensure a smooth transition. Tecan will nominate her successor in due time, leveraging the company’s succession planning process.お知らせ • Oct 13Tecan Reaffirms Earnings Guidance for the Year 2025Tecan reaffirmed earnings guidance for the year 2025. For the year, Tecan confirmed its full-year sales outlook, expecting sales in local currencies to be within the previously communicated range – from a low single-digit percentage decline to low single-digit percentage growth, with current trends indicating that full-year performance will be in the lower half of the range. Tecan also reiterates its mid-term outlook, anticipating a return to average organic growth rates in the mid- to high-single-digit percentage range in local currencies under normal market conditions, while continuously improving profitability. However, end markets are expected to recover gradually, so a full normalization is not anticipated in 2026. Guidance for 2026 will be provided, as usual, with the full-year 2025 results in March 2026.お知らせ • Oct 10Tecan Group AG to Report Fiscal Year 2025 Results on Mar 16, 2026Tecan Group AG announced that they will report fiscal year 2025 results on Mar 16, 2026お知らせ • Sep 13Tecan Group AG Announces Change of Leadership in the Partnering Business DivisionThe Tecan Group announced a change of leadership in its Partnering Business division. Ralf Griebel, who has served as Head of the Partnering Business division and as a member of the Management Board since April 2020, will be leaving the Company to pursue other opportunities. Monica Manotas will assume interim leadership of the Partnering Business division, taking this as an opportunity to work more closely with the business.お知らせ • Apr 04Tecan Group AG (SWX:TECN) signed an agreement to acquire Certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS.Tecan Group AG (SWX:TECN) signed an agreement to acquire Certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS on April 3, 2025. The asset purchase includes the manufacturing process of four ELISA kits – two in vitro diagnostic (IVD) products for specialty diagnostics and disease monitoring, and two research-use-only (RUO) kits. To ensure uninterrupted availability of these four ELISA kits until completion of the asset transfer, IBL International GmbH, a Tecan company, has signed a Master Distributorship Agreement with Cisbio Bioassays to resell the kits.お知らせ • Mar 24Tecan Group AG(SWX:TECN) dropped from FTSE All-World Index (USD)Tecan Group AG(SWX:TECN) dropped from FTSE All-World Index (USD)お知らせ • Mar 19Tecan Group AG, Annual General Meeting, Apr 10, 2025Tecan Group AG, Annual General Meeting, Apr 10, 2025, at 15:00 W. Europe Standard Time.お知らせ • Mar 12+ 1 more updateTecan Group Ag Proposes Cash Dividend for the Year 2024Based on the solid cash flows for the full year 2024 and on the basis of an ongoing positive business outlook, the Board of Directors of Tecan Group AG will propose at the Company’s Annual General Meeting on April 18, 2025, an unchanged dividend of CHF 3.00 per share. Half of the dividend, i.e., CHF 1.50, will again be paid out from the available capital contribution reserve and is therefore not subject to withholding tax.お知らせ • Mar 06Tecan Group AG to Report Q4, 2024 Results on Jun 12, 2025Tecan Group AG announced that they will report Q4, 2024 results at 6:00 AM, Central European Standard Time on Jun 12, 2025お知らせ • Jan 28Tecan Introduces Veya: Bringing Digital, Scalable Automation to Labs WorldwideTecan announced the unveiling of Veya™, a transformative liquid handling platform designed to bring efficiency, precision and compliance to laboratories of all sizes. The platform, showcased at the Society for Laboratory Automation and Screening (SLAS) international conference, San Diego, underscores Tecan’s continued commitment to innovation and the democratization of lab automation. Veya overcomes key barriers in lab automation by offering an accessible and versatile platform that streamlines complex workflows and enables data-driven decision-making, while reducing downtime and enhancing productivity. Veya combines AI-enhanced automation, prebuilt workflows and an intuitive analytics interface, OneView™, to simplify complex tasks, including multiomics workflows. Its seamless integration with existing systems enables laboratories to boost productivity and meet important regulatory standards, including Europe’s CE-IVD and IVDR requirements. Key features of Veya: Simplified automation: Predeveloped workflows, intelligent analytics and a modular design boost productivity while reducing errors. Users report improvements of more than 60% in instrument utilization. High precision: Equipped with patented Air Restriction Pipetting (ARP), Veya handles volumes from 1 µl to 5 ml with precision. Real-time data: Improves decision-making and process optimization with live monitoring and actionable insights via a user-friendly interface. Continuous support: Features include 24-hour remote diagnostics, remote-guided troubleshooting and tailored service packages to minimize unplanned interruptions. Regulatory compliance: Veya is ideal for labs in regulated environments, ensuring compliance with key industry standards and regulatory requirements. Veya reflects Tecan’s commitment to democratize automation for laboratories of all sizes, including those constrained by budget or resources. By providing scalable, versatile and intuitive solutions for the ever-evolving needs of scientific research and diagnostics, Tecan continues to scale healthcare innovation globally.お知らせ • Dec 17Tecan Group AG to Report First Half, 2025 Results on Aug 12, 2025Tecan Group AG announced that they will report first half, 2025 results on Aug 12, 2025お知らせ • Aug 13+ 1 more updateTecan Group AG Revises Earnings Guidance for the Year 2024Tecan Group AG revised earnings guidance for the year 2024. Based on the financial results from the first half of the year, Tecan has revised its full-year outlook. This revision is also due to the anticipation that weaker demand, driven by general market weakness, will persist longer than originally expected, while the new China stimulus program is likely to have a meaningful impact only from 2025. The company now expects full-year 2024 sales in local currencies to range from on prior-year level to a decrease in the mid single-digit percentage range (previously expected to increase in the low single-digit percentage range in local currencies).お知らせ • Jun 25Tecan Appoints Mukta Acharya as Head of the Life Sciences Business Division, Effective from August 1, 2024Tecan Group AG announced that Mukta Acharya, currently serving as President, Tecan Americas, has been appointed the new Head of the Life Sciences Business division and a member of the Management Board of the Tecan Group. She is expected to assume her new position on August 1, 2024. Dr. Klaus Lun, Head of the Life Sciences Business since 2017 and a member of the Management Board since 2013, has decided to leave the company to pursue other career opportunities. Mukta Acharya joined Tecan in July 2022 as President, Tecan Americas, where she was responsible for the successful financial and market performance of the Life Sciences Business division in the company’s sales region. Mukta Acharya joined Tecan from Thermo Fisher Scientific, where she most recently served as Vice President and General Manager of the Single-use Flexible Solutions business. In this role, she drove the strategic growth of the global business, which spanned multiple manufacturing sites and thousands of employees worldwide. She also oversaw product management, marketing, engineering, and business development across the organization's various business units. From 2010 to 2018, Mukta Acharya held leadership positions at CVS Health, most recently as Director, Enterprise Product Innovation & Management. Prior to that, she worked in management consulting. She has a bachelor’s degree in Mechanical Engineering from India and a master’s degree in Engineering Management from Dartmouth College in the United States. Under Klaus Lun’s leadership, the Life Sciences Business division achieved significant growth and successfully navigated the challenges of the Covid-19 pandemic. Tecan’s Board of Directors and CEO would like to express their sincere gratitude to Klaus Lun for his strong engagement and important service of developing Tecan's Life Sciences Business and wish him all the best for the future.お知らせ • Apr 20Tecan Group Approves Dividend, Payable on April 24, 2024Tecan Group announced that at its AGM held on April 18, 2024, shareholders approved to an increase in the dividend from CHF 2.90 to CHF 3.00 per registered share. Half of the dividend, i.e., CHF 1.50, will be paid out from the available capital contribution reserve and is therefore not subject to withholding tax. The payout will take place on April 24, 2024.お知らせ • Apr 19Tecan Group Elects Monica Manotas as Additional Independent Member of the Board of DirectorsTecan Group announced that at its AGM held on April 18, 2024, the shareholders elected Monica Manotas as an additional independent member of the Tecan Board of Directors. With her many years of international experience in the life science industry and her proven expertise in finance, the industrial engineer with Colombian and US citizenship will strengthen the Board in a variety of ways.お知らせ • Mar 14+ 1 more updateTecan Group AG Provides Earnings Guidance for the Year 2024Tecan Group AG provided earnings guidance for the year 2024. For the year, the company expects Sales growth expected in the low single-digit percentage range in local currencies.お知らせ • Feb 06Tecan Group AG to Report First Half, 2024 Results on Aug 13, 2024Tecan Group AG announced that they will report first half, 2024 results on Aug 13, 2024お知らせ • Aug 17Tecan Group AG Provides Earnings Guidance for the Full Year 2023Tecan Group AG provided earnings guidance for the full year 2023. For the year, the company continues to forecast sales to increase in the low to mid single-digit percentage range in local currencies. This expectation includes the negative impact of lower COVID-related sales (approximately -4% points for the full year 2023, with the largest share of the impact already recorded in the first half of the year) and the reduced pass-through of material costs (at least -1% point). Underlying sales, which exclude these negative effects, are expected to grow in the high single-digit percentage range in local currencies.お知らせ • Aug 16Tecan Group AG to Report Fiscal Year 2023 Results on Mar 12, 2024Tecan Group AG announced that they will report fiscal year 2023 results on Mar 12, 2024お知らせ • Aug 15Tecan Group AG, Annual General Meeting, Apr 18, 2024Tecan Group AG, Annual General Meeting, Apr 18, 2024.お知らせ • Dec 08Tecan Group AG to Report First Half, 2023 Results on Aug 15, 2023Tecan Group AG announced that they will report first half, 2023 results on Aug 15, 2023お知らせ • Aug 17Tecan Group AG, Annual General Meeting, Apr 18, 2023Tecan Group AG, Annual General Meeting, Apr 18, 2023.収支内訳Tecan Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:TCHB.F 収益、費用、利益 ( )CHF Millions日付収益収益G+A経費研究開発費31 Dec 25882-1112006730 Sep 25895-241916630 Jun 25907631827131 Mar 25920651837031 Dec 24934681846330 Sep 24967851886330 Jun 241,0001011926431 Mar 241,0371171926731 Dec 231,0741321927030 Sep 231,0881201987430 Jun 231,1021092057831 Mar 231,1231152097831 Dec 221,1441212147830 Sep 221,1101132127930 Jun 221,0771052107931 Mar 221,0121132017631 Dec 219471221927230 Sep 219111361927030 Jun 218751501916831 Mar 218031271826531 Dec 207311041726230 Sep 20691941605930 Jun 20651841495631 Mar 20644791495831 Dec 19637731496030 Sep 19627701505930 Jun 19616671515931 Mar 19605691465531 Dec 18594711415130 Sep 18582701395030 Jun 18570691384931 Mar 18559671375031 Dec 17549661365030 Sep 17536621324930 Jun 17523571294831 Mar 17515561274731 Dec 16506551254730 Sep 16491551234530 Jun 16476551204331 Mar 16458561154131 Dec 15440571104030 Sep 15434521084130 Jun 154274810642質の高い収益: TCHB.Fは現在利益が出ていません。利益率の向上: TCHB.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: TCHB.Fは利益が出ておらず、過去 5 年間で損失は年間25.5%の割合で増加しています。成長の加速: TCHB.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: TCHB.Fは利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( 3.8% ) と比較することは困難です。株主資本利益率高いROE: TCHB.Fは現在利益が出ていないため、自己資本利益率 ( -9.61% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/08 07:43終値2026/04/17 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Tecan Group AG 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Harry GillisBerenbergDelphine Le LouetBernsteinSusannah LudwigBernstein15 その他のアナリストを表示
お知らせ • Dec 19Tecan Group AG to Report First Half, 2026 Results on Aug 11, 2026Tecan Group AG announced that they will report first half, 2026 results on Aug 11, 2026
お知らせ • Oct 10Tecan Group AG to Report Fiscal Year 2025 Results on Mar 16, 2026Tecan Group AG announced that they will report fiscal year 2025 results on Mar 16, 2026
お知らせ • Mar 06Tecan Group AG to Report Q4, 2024 Results on Jun 12, 2025Tecan Group AG announced that they will report Q4, 2024 results at 6:00 AM, Central European Standard Time on Jun 12, 2025
お知らせ • Dec 17Tecan Group AG to Report First Half, 2025 Results on Aug 12, 2025Tecan Group AG announced that they will report first half, 2025 results on Aug 12, 2025
お知らせ • Feb 06Tecan Group AG to Report First Half, 2024 Results on Aug 13, 2024Tecan Group AG announced that they will report first half, 2024 results on Aug 13, 2024
お知らせ • Aug 16Tecan Group AG to Report Fiscal Year 2023 Results on Mar 12, 2024Tecan Group AG announced that they will report fiscal year 2023 results on Mar 12, 2024
お知らせ • Apr 16Tecan Group Ag Announces Executive ChangesTecan Group AG in its AGM meeting held on April 15, 2026, announced that shareholders elected three new members of the Board of Directors: Nina Beikert, Gitte Pugholm Aabo and Guillaume Daniellot. Matthias Gillner, who has been a member of the Board of Directors since 2023 and its Vice-Chairman, was elected as the new Chairman. He will step down as Chair of the Audit Committee but will remain a member, alongside Guillaume Daniellot and Gitte Pugholm Aabo. With the addition of the newly elected members, the Board of Directors will once again comprise seven members, ensuring an optimal balance of expertise, skills, and experience for the future. Lukas Braunschweiler, Chairman and a member of the Board since 2018, did not stand for re-election.
お知らせ • Mar 30The Tecan Group Announces the Appointment of Camila Japur as Chief Financial Officer, Effective on June 1, 2026The Tecan Group announced the appointment of Camila Japur as Chief Financial Officer, who will join the company on June 1, 2026. Camila currently serves as Group CFO of u-blox, where she has successfully led transformation initiatives, driving cost efficiency, strengthening financial processes, and enhancing capital market engagement. Prior to this, Camila spent 24 years at Ericsson, including seven years as CFO for the Enterprise Segment. Camila has an MBA from Fundação Getulio Vargas in São Paulo and a Bachelor's Degree in Economics from Universidade Mackenzie in São Paulo.
お知らせ • Mar 25Tecan Group AG Announces Member of the Board of Directors Oliver Fetzer Will Not Stand for Re-ElectionTecan Group AG announced that Oliver Fetzer, a member of the Board since 2011, has decided not to stand for re-election at the AGM to be held on April 15, 2026.
お知らせ • Mar 16+ 1 more updateTecan Group AG Proposes Dividend for the Full Year 2025The Board of Directors of Tecan Group AG will propose an unchanged dividend of CHF 3.00 per share at the Annual General Meeting on April 15, 2026 for the full year 2025. Half of the dividend, i.e., CHF 1.50, will again be paid out from the available capital contribution reserve and is therefore not subject to withholding tax.
お知らせ • Dec 19Tecan Group AG to Report First Half, 2026 Results on Aug 11, 2026Tecan Group AG announced that they will report first half, 2026 results on Aug 11, 2026
お知らせ • Dec 05Tecan Group AG, Annual General Meeting, Apr 15, 2026Tecan Group AG, Annual General Meeting, Apr 15, 2026.
お知らせ • Dec 04ecan Group AG Announces Chairman of the Board of Directors Lukas Braunschweiler Will Not Stand for Re-ElectionTecan Group AG announced that Lukas Braunschweiler, Chairman of the Board of Directors and a member of the Board since 2018, will not stand for re-election.
お知らせ • Dec 02Tecan Group AG (SWX:TECN) acquired Wako Automation.Tecan Group AG (SWX:TECN) acquired Wako Automation on December 1, 2025. Tecan Group AG (SWX:TECN) completed the acquisition of Wako Automation on December 1, 2025.
お知らせ • Nov 17+ 1 more updateTecan Group AG Announces Departure of Tania Micki as Member of the Management BoardTecan Group AG announced that Tania Micki, member of the Management Board since February 2020, will be leaving the company to pursue an external opportunity. She will continue in her role through May 2026 to ensure a smooth transition. Tecan will nominate her successor in due time, leveraging the company’s succession planning process.
お知らせ • Oct 13Tecan Reaffirms Earnings Guidance for the Year 2025Tecan reaffirmed earnings guidance for the year 2025. For the year, Tecan confirmed its full-year sales outlook, expecting sales in local currencies to be within the previously communicated range – from a low single-digit percentage decline to low single-digit percentage growth, with current trends indicating that full-year performance will be in the lower half of the range. Tecan also reiterates its mid-term outlook, anticipating a return to average organic growth rates in the mid- to high-single-digit percentage range in local currencies under normal market conditions, while continuously improving profitability. However, end markets are expected to recover gradually, so a full normalization is not anticipated in 2026. Guidance for 2026 will be provided, as usual, with the full-year 2025 results in March 2026.
お知らせ • Oct 10Tecan Group AG to Report Fiscal Year 2025 Results on Mar 16, 2026Tecan Group AG announced that they will report fiscal year 2025 results on Mar 16, 2026
お知らせ • Sep 13Tecan Group AG Announces Change of Leadership in the Partnering Business DivisionThe Tecan Group announced a change of leadership in its Partnering Business division. Ralf Griebel, who has served as Head of the Partnering Business division and as a member of the Management Board since April 2020, will be leaving the Company to pursue other opportunities. Monica Manotas will assume interim leadership of the Partnering Business division, taking this as an opportunity to work more closely with the business.
お知らせ • Apr 04Tecan Group AG (SWX:TECN) signed an agreement to acquire Certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS.Tecan Group AG (SWX:TECN) signed an agreement to acquire Certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS on April 3, 2025. The asset purchase includes the manufacturing process of four ELISA kits – two in vitro diagnostic (IVD) products for specialty diagnostics and disease monitoring, and two research-use-only (RUO) kits. To ensure uninterrupted availability of these four ELISA kits until completion of the asset transfer, IBL International GmbH, a Tecan company, has signed a Master Distributorship Agreement with Cisbio Bioassays to resell the kits.
お知らせ • Mar 24Tecan Group AG(SWX:TECN) dropped from FTSE All-World Index (USD)Tecan Group AG(SWX:TECN) dropped from FTSE All-World Index (USD)
お知らせ • Mar 19Tecan Group AG, Annual General Meeting, Apr 10, 2025Tecan Group AG, Annual General Meeting, Apr 10, 2025, at 15:00 W. Europe Standard Time.
お知らせ • Mar 12+ 1 more updateTecan Group Ag Proposes Cash Dividend for the Year 2024Based on the solid cash flows for the full year 2024 and on the basis of an ongoing positive business outlook, the Board of Directors of Tecan Group AG will propose at the Company’s Annual General Meeting on April 18, 2025, an unchanged dividend of CHF 3.00 per share. Half of the dividend, i.e., CHF 1.50, will again be paid out from the available capital contribution reserve and is therefore not subject to withholding tax.
お知らせ • Mar 06Tecan Group AG to Report Q4, 2024 Results on Jun 12, 2025Tecan Group AG announced that they will report Q4, 2024 results at 6:00 AM, Central European Standard Time on Jun 12, 2025
お知らせ • Jan 28Tecan Introduces Veya: Bringing Digital, Scalable Automation to Labs WorldwideTecan announced the unveiling of Veya™, a transformative liquid handling platform designed to bring efficiency, precision and compliance to laboratories of all sizes. The platform, showcased at the Society for Laboratory Automation and Screening (SLAS) international conference, San Diego, underscores Tecan’s continued commitment to innovation and the democratization of lab automation. Veya overcomes key barriers in lab automation by offering an accessible and versatile platform that streamlines complex workflows and enables data-driven decision-making, while reducing downtime and enhancing productivity. Veya combines AI-enhanced automation, prebuilt workflows and an intuitive analytics interface, OneView™, to simplify complex tasks, including multiomics workflows. Its seamless integration with existing systems enables laboratories to boost productivity and meet important regulatory standards, including Europe’s CE-IVD and IVDR requirements. Key features of Veya: Simplified automation: Predeveloped workflows, intelligent analytics and a modular design boost productivity while reducing errors. Users report improvements of more than 60% in instrument utilization. High precision: Equipped with patented Air Restriction Pipetting (ARP), Veya handles volumes from 1 µl to 5 ml with precision. Real-time data: Improves decision-making and process optimization with live monitoring and actionable insights via a user-friendly interface. Continuous support: Features include 24-hour remote diagnostics, remote-guided troubleshooting and tailored service packages to minimize unplanned interruptions. Regulatory compliance: Veya is ideal for labs in regulated environments, ensuring compliance with key industry standards and regulatory requirements. Veya reflects Tecan’s commitment to democratize automation for laboratories of all sizes, including those constrained by budget or resources. By providing scalable, versatile and intuitive solutions for the ever-evolving needs of scientific research and diagnostics, Tecan continues to scale healthcare innovation globally.
お知らせ • Dec 17Tecan Group AG to Report First Half, 2025 Results on Aug 12, 2025Tecan Group AG announced that they will report first half, 2025 results on Aug 12, 2025
お知らせ • Aug 13+ 1 more updateTecan Group AG Revises Earnings Guidance for the Year 2024Tecan Group AG revised earnings guidance for the year 2024. Based on the financial results from the first half of the year, Tecan has revised its full-year outlook. This revision is also due to the anticipation that weaker demand, driven by general market weakness, will persist longer than originally expected, while the new China stimulus program is likely to have a meaningful impact only from 2025. The company now expects full-year 2024 sales in local currencies to range from on prior-year level to a decrease in the mid single-digit percentage range (previously expected to increase in the low single-digit percentage range in local currencies).
お知らせ • Jun 25Tecan Appoints Mukta Acharya as Head of the Life Sciences Business Division, Effective from August 1, 2024Tecan Group AG announced that Mukta Acharya, currently serving as President, Tecan Americas, has been appointed the new Head of the Life Sciences Business division and a member of the Management Board of the Tecan Group. She is expected to assume her new position on August 1, 2024. Dr. Klaus Lun, Head of the Life Sciences Business since 2017 and a member of the Management Board since 2013, has decided to leave the company to pursue other career opportunities. Mukta Acharya joined Tecan in July 2022 as President, Tecan Americas, where she was responsible for the successful financial and market performance of the Life Sciences Business division in the company’s sales region. Mukta Acharya joined Tecan from Thermo Fisher Scientific, where she most recently served as Vice President and General Manager of the Single-use Flexible Solutions business. In this role, she drove the strategic growth of the global business, which spanned multiple manufacturing sites and thousands of employees worldwide. She also oversaw product management, marketing, engineering, and business development across the organization's various business units. From 2010 to 2018, Mukta Acharya held leadership positions at CVS Health, most recently as Director, Enterprise Product Innovation & Management. Prior to that, she worked in management consulting. She has a bachelor’s degree in Mechanical Engineering from India and a master’s degree in Engineering Management from Dartmouth College in the United States. Under Klaus Lun’s leadership, the Life Sciences Business division achieved significant growth and successfully navigated the challenges of the Covid-19 pandemic. Tecan’s Board of Directors and CEO would like to express their sincere gratitude to Klaus Lun for his strong engagement and important service of developing Tecan's Life Sciences Business and wish him all the best for the future.
お知らせ • Apr 20Tecan Group Approves Dividend, Payable on April 24, 2024Tecan Group announced that at its AGM held on April 18, 2024, shareholders approved to an increase in the dividend from CHF 2.90 to CHF 3.00 per registered share. Half of the dividend, i.e., CHF 1.50, will be paid out from the available capital contribution reserve and is therefore not subject to withholding tax. The payout will take place on April 24, 2024.
お知らせ • Apr 19Tecan Group Elects Monica Manotas as Additional Independent Member of the Board of DirectorsTecan Group announced that at its AGM held on April 18, 2024, the shareholders elected Monica Manotas as an additional independent member of the Tecan Board of Directors. With her many years of international experience in the life science industry and her proven expertise in finance, the industrial engineer with Colombian and US citizenship will strengthen the Board in a variety of ways.
お知らせ • Mar 14+ 1 more updateTecan Group AG Provides Earnings Guidance for the Year 2024Tecan Group AG provided earnings guidance for the year 2024. For the year, the company expects Sales growth expected in the low single-digit percentage range in local currencies.
お知らせ • Feb 06Tecan Group AG to Report First Half, 2024 Results on Aug 13, 2024Tecan Group AG announced that they will report first half, 2024 results on Aug 13, 2024
お知らせ • Aug 17Tecan Group AG Provides Earnings Guidance for the Full Year 2023Tecan Group AG provided earnings guidance for the full year 2023. For the year, the company continues to forecast sales to increase in the low to mid single-digit percentage range in local currencies. This expectation includes the negative impact of lower COVID-related sales (approximately -4% points for the full year 2023, with the largest share of the impact already recorded in the first half of the year) and the reduced pass-through of material costs (at least -1% point). Underlying sales, which exclude these negative effects, are expected to grow in the high single-digit percentage range in local currencies.
お知らせ • Aug 16Tecan Group AG to Report Fiscal Year 2023 Results on Mar 12, 2024Tecan Group AG announced that they will report fiscal year 2023 results on Mar 12, 2024
お知らせ • Aug 15Tecan Group AG, Annual General Meeting, Apr 18, 2024Tecan Group AG, Annual General Meeting, Apr 18, 2024.
お知らせ • Dec 08Tecan Group AG to Report First Half, 2023 Results on Aug 15, 2023Tecan Group AG announced that they will report first half, 2023 results on Aug 15, 2023
お知らせ • Aug 17Tecan Group AG, Annual General Meeting, Apr 18, 2023Tecan Group AG, Annual General Meeting, Apr 18, 2023.